#1Allurion#2A Disclaimer Forward-Looking Statements Certain statements, estimates, targets and projections in this presentation may be considered "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events or future performance of Allurion Technologies, Inc. (the "Company"). For example, projections of future revenue, costs of goods sold, gross profit, sales and marketing and general and administrative expenses and EBIT; anticipated growth in the industry in which the Company operates and anticipated growth in demand for the Company's products; the launch of the Company's products in new markets, regulatory approvals for its products, including any expanded label uses; the total addressable markets for the Company's products; new product developments and offerings, including the Company's digital health platform and artificial intelligence are forward-looking statements. In some cases, you can identify forward-looking statements through the use of words or phrases such as "pro forma", "may", "should", "could", "might", "possible", "project", "target", "strive", "budget", "forecast", "intend", "estimate", "anticipate", "predict", "potential", "believe", "will likely result", "expect", "continue", "will", "anticipate", "seek", "estimate", "intend", "plan", "projection", "would" and "outlook", or the negative version of those words or phrases or other comparable words or phrases of a future or forward-looking nature. These forward- looking statements are not historical facts and are based upon estimates and assumptions that, while considered reasonable by the Company and its management are inherently uncertain. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.. All information set forth herein speaks as of the date hereof unless otherwise indicated and the Company disclaims any intention or obligation to update any forward-looking statements or other information as a result of events occurring after this presentation. Projected and estimated numbers are used for illustrative purposes only, are not forecasts and may not, and are likely not to, reflect actual results. Industry and Market Data Unless otherwise indicated, information contained in this presentation concerning the Company's industry, competitive position and the markets in which it operates is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third-party sources, as well as data from the Company's internal research, and are based on assumptions made by the Company upon reviewing such data, and the Company's experience in, and knowledge of, such industry and markets, which the Company believes to be reasonable. While the Company believes that such third party information is reliable, the Company has not independently verified, and makes no representation as to the accuracy or completeness of, such third party information. In addition, projections, assumptions and estimates of the future performance of the industry in which the Company operates and the Company's future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described above. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company. Trademarks The trademarks, service marks, trade names and copyrights included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company.#3A We have one goal: End Obesity#4A Allurion Aims to Solve One of the Biggest Problems in Healthcare, is Growing at an Exceptional Rate, and is Nearing Several Multi-Billion Dollar Catalysts 1 2 3 LO Obesity is one of the biggest unmet medical needs in the world and new GLP-1 drugs have unlocked a $50B+ revenue opportunity¹ 5 Allurion delivers on average 30 pounds of weight loss and remission of Type 2 Diabetes in just 4 months and 95% weight maintenance at 1-year² 4 Expanding generative Al platform with launch of Coach Iris, a 24/7 GPT-powered health coach 100,000+ patients treated in established distribution channels with clear path to 80%+ margins Additional regulatory approvals, product pipeline, and digital platform expansion are catalysts for future opportunities Sources: 1) Morgan Stanley, "Unlocking the Obesity Challenge: a >$50BN Market"; 2) Obes Surg. 2020; 20(9):3354-62. lenca et al. Obesity Week 2020 and 2021.#5A Allurion Is Going Public With Wind At Its Sails $1 Record High Revenue $3 $7 $13 $20 $38 $64 2016 2017 2018 2019 2020 2021 2022 Key Milestones 100,000+ patients in 50+ countries 2.5 million app sessions in 2022 78% gross margin in 2022 40+ patents issued FDA Trial Launch ▸ No safety signals Enrollment at 75% and ahead of schedule SAB Additions Bob Langer New Data 15%+ weight loss Reginal Barzilay ▸ Crossed 15% weight loss barrier Presented at SAGES and ECO#6The Problem Allurion PROGRAM 10:56#7A Why We Believe Other Weight Loss Innovations Fail Poor Experience Lack of remote patient monitoring and behavior modification High Risks Invasive procedures are inherently risky in a high BMI population¹ ASA. https://www.asahq.org/madeforthismoment/preparing-for-surgery/risks/obesity/. (1) (2) ObesityCoverage.com, https://www.obesitycoverage.com/weight-loss-surgery-insurance-coverage-and-costs/. (3) GoodRx, https://www.goodrx.com/wegovy. Poor Economics Bariatric surgery is estimated to be $15,000 out-of-pocket² Drugs are estimated to be $1,000 per month³ Limited Channels Most providers lack infrastructure and training to deliver comprehensive weight loss Flawed Go- To-Market Execution Previous companies failed to embrace modern-day digital advertising and account training techniques to drive growth 7#8A The Time is Now: GLP-1 Drugs Created Unprecedented Interest in Weight Loss and Unlocked a $50 Billion Revenue Opportunity Obesity: $50B+ Revenue Market by 2030 $bn 60 50 40 30 20 10 2024 2025 US revenues Saxenda liraglutide injection 3 mg 2015 2026 2027 Ex-US revenues ONCE-WEEKLY 2028 2017 2029 semaglutide injection ng mg 1mg *Sources: Morgan Stanley. "Unlocking the Obesity Challenge: a >$50BN Market" 2030 High-efficacy patient share 10% 9% 8% 7% 6% 5% 4% 3% 2% 1% 0% 100 90 80 70 60 50 40 30 20 10 0 2019 GLP-1 Drug Approvals RYBELSUSⓇ semaglutide tablets GLP-1s Made Obesity Mainstream Jan-13 Oct-13 Jul-14 Apr-15 Oct-16 Jan-16 Launch of Ozempic (semaglutide in diabetes) Jul-17 2021 wegovy® semaglutide injection 2.4 mg Apr-18 Launch of Wegovy (semaglutide in obesity) Jan-19 Oct-19 -Diabetes drug for weight loss: (Worldwide) -Semaglutide: (Worldwide) Jul-20 Apr-21 Jan-22 HALO EFFECT mounjaro (tirzepatide) injection 2022#9A GLP-1 Drugs Face Several Challenges Allurion Can Capitalize Upon Poor Experience Weekly injection Real-world drop- out rates of 45-65%¹ Loss of muscle mass³ 19.9 High Risks Thyroid cancer associated with long-term use² 9.8% serious adverse event rate³ High Costs $1,000 per month with limited insurance coverage4 000 Weight Re-Gain Weight is re- gained quickly if drugs are stopped5 Sources: 1) Weiss et al. BMJ Open Diab Res and Care 2022;10:e002517. 2) Bezin et al. Diabetes Care 2023;46(2):384-91. 3) Wilding et al. N Engl J Med 2021;384:989-1002, 4) GoodRx. https://www.goodrx.com/wegovy. 5) Wilding et al. Diabetes Obes Metab. 2022;24(8): 1553-64.#10Our Solution Allurion PROGRAM 10:56#11A The Allurion Program Combines a Revolutionary Medical Device, Cutting-Edge Digital Therapeutic, and Behavior Change Program The Allurion® Balloon The world's first and only procedurelessTM weight loss device Swallowed and passed 4 months later 10:56 Allurion Iris Al Platform Al-powered digital therapeutic and remote patient monitoring solution Seamlessly integrated into the weight loss program A My Weight Loss Actions Stedly "Honeymoon from Hunger" Behavior Change Program Clinically proven program featuring 150 weight loss actions Aims to deliver weight loss for life#12A Al in Action: The Success Predictor ► Proprietary algorithm trained on millions of data points from over 7,000 Allurion patients ► Identifies "off-track" patients as early as 20 days into the Program ► Enables providers to intervene sooner and get patients back on track Allurion INVIGHTS Clinic Overview 52 Active Patients Wa V A 12 Clinic Trends Active Patients imen Success Predictor ▲ > ▲ 70% 312 R ** TOWL 83% M B Paka Dwye 708 P a B 12 ©2021 ALLURION TECHNOLOGIES-PROPRIETARY INFORMATION-CONFIDENTIAL#13A Meet Coach Iris: Coming 2H-23 A 24/7 Weight Loss Coach Powered by ChatGPT Fine-Tuned to the Allurion Behavior Change Program Key Features ► 24/7 weight loss coach ▸ Powered by ChatGPT ► Trained on the proprietary Allurion Behavior Change Program and millions of data points on weight, activity, sleep, and heart rate Designed to support long-term weight loss and maintenance 13#14A Using Generative Al, Coaching Can Be Fully Personalized Across 50 Markets DO B2C Vision Build an infinite army of 24/7 weight loss coaches personalized to each consumer and localized to each of our 50+ markets COF B2B Vision Create custom, 24/7 weight loss coaches tailored to individual physician practices that augment human providers 14#15A Allurion Patients Achieve 30 Pounds of Life-Changing Weight Loss on Average and Keep 95% of it Off at 1-Year Weight Loss 30 pounds with 1 balloon at 4 months O O 50 pounds with 2 balloons at 12 months Weight Maintenance 95% at 12 months 30 pounds at 4 months Sources: Obes Surg. 2020; 2019):3354-62. lenca et al. Obesity Week 2020 and 2021. All values shown on slide are means. 29 pounds at 12 months Diabetes Remission -1.5 HbA1c -1.5 in HbA1c in diabetics -1.1 in HbA1c in prediabetics 15#16A New Clinical Studies Report 15%+ Weight Loss V&SX SAGES 2023 Boosting Long-Term Results 232 patient study with 1- year follow-up ► Allurion Balloon therapy for the first 4 months with ongoing lifestyle modification after balloon passage ► 17% total body weight loss at 1 year Sources: Raftopoulos and Rajkumar, SAGES 2023; lenca et al, ECO 2023. ECO 2023 17-20 May, 2023 Dublin, Ireland Balloon + Drug: A New Paradigm 181 patient study combining Allurion Balloon with GLP-1 weight loss drug ► 19% total body weight loss at 8 months First multi-center study on balloon + drug combination therapy demonstrating significant synergies 16#17Future Opportunities Allurion PROGRAM r fut Pine pratite Uve *** P Meta WARN wa hu (MOLE NOW LAMA VER IKASIA JUMPM) 112 Je Man MILE md 47 wmst " You ive Mu (y₁ues) Lon pe ( mine 2 wolled Flock TIM LO Arm (M.#18A Our 3-Year Strategy KY Expand revenues in existing markets Launch in new markets Expand our platform to engage patients for a lifetime 18#19A Expand Revenues in Existing Markets Even at 100% CAGR, our TAM is still untapped 80-200+% CAGR in top direct markets 5000 4500 4000 3500 3000 2500 2000 1500 1000 500 0 France 0.10% 0.09% 0.08% 0.07% 0.06% 0.05% 86% CAGR M 2017 2018 2019 2020 2021 Balloons Sold -Penetration 0.04% 0.03% 0.02% 0.01% 0.00% High growth across all regions globally 8000 7000 6000 5000 4000 3000 2000 1000 0 Spain 0.30% 89% CAGR fil 0.25% 0.20% 0.15% 0.10% 0.05% 0.00% 2017 2018 2019 2020 2021 Balloons Sold -Penetration <0.2% penetration rate globally 3500 3000 2500 2000 1500 1000 500 0 UK 227% CAGR M 2017 2018 2019 2020 2021 Balloons Sold -Penetration Reaching 1% penetration in just existing markets today translates to ~$500M of annual revenue 0.06% 0.05% 0.04% 0.03% 0.02% 0.01% 0.00%#20A Anticipated Launches in High Potential New Markets* Future Market Openings Will Drive Continued Growth 700M PAR Across 44 countries 2021 1.1B *) C 2022 1.3B 2023 Source: Allurion Market Research. "Values denote estimated number of individuals with BMI 25+ in launched territories. Only select countries are listed. 2 Billion 2024+ 20#21A IDE for AUDACITY Trial Has Been Approved by FDA Enrollment begun in May 2022 Treatment Group (n= 250) Control Group (n = 250) °C WO | Co-Primary 50% responder rate Endpoints: (>5% TBWL) at 48 weeks 8 Open-label, sequential balloon 88 design is expected to boost weight loss and durability IDE- Investigational Device Exemption Balloon 1 W16 W24 Moderate Intensity Lifestyle Therapy Moderate Intensity Lifestyle Therapy M Break 3.0% total body weight loss (TBWL) superiority margin at 48 weeks Balloon 2 Conservative sample size and powering W40 W48 Break 48-week endpoint may open door to reimbursement 21#22A Sequential Use of Allurion Balloon In a study of 42 patients, sequential balloon use led to an average weight loss of 22kg at 1-year % Total Body Weight Loss 0.0 -5.0 -10.0 -15.0 -20.0 -25.0 -30.0 Balloon #1 -14% Break Balloon #2 +2% -10% Sources: lenca et al. Sequential Elipse Balloon Treatment: 1-Year Weight Loss Results Approximate Bariatric Surgery Results. -23% % Total Body Weight Loss Responder Rate %TBWL ≥5% ≥10% ≥20% ≥30% % of Patients 100% 97.6% 64.7% 26.1% 22#23A Allurion is Building an Al-Powered, Full-Stack Weight Loss Platform Q PATIENT A Al-powered Treatment Selection A Al-powered Coaching and RPM O BALLOON MEDICATION SURGERY A Al-powered Treatment Pathing 23#24A Key Highlights 1 2 3 Large Addressable Market with tailwinds created by GLP-1s Fast and Sustainable Weight Loss Experience Powered by Al Growing at an Exceptional Rate with Clear Path to 80%+ Margins 4 5 6 Strong Competitive Moat with Broad Patent Coverage Creates a High Barrier to Entry Going Public with Seasoned Strategic and Financial Partners Regulatory Approvals, Digital Platform Expansion, and Pipeline will Fuel Profitable Future Growth 24 ©2023 ALLURION TECHNOLOGIES-PROPRIETARY INFORMATION-CONFIDENTIAL#25Allurion